Serstech
Serstech receives 1.7 MSEK order from its partner Proengin
Serstech receives 1.7 MSEK order from its partner Proengin
Serstech has today received a 1.7 MSEK order from its French partner Proengin.
The order consists of both hardware and software and will be delivered and invoiced before the end of Q4 2025.
For further information, please contact:
Stefan Sandor,
CEO, Serstech AB Phone: +46 739 606 067
Email: ss@serstech.com
or
Thomas Pileby,
Chairman of the Board, Serstech AB Phone: +46 702 072 643
Email: tp@serstech.com
or visit: www.serstech.com
This is information that Serstech AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 11:15 CET on November 5, 2025.
Certified advisor to Serstech is Svensk Kapitalmarknadsgranskning AB (SKMG).
About Serstech
Serstech delivers solutions for chemical identification and has customers around the world, mainly in the safety and security industry. Typical customers are customs, police authorities, security organizations and first responders. The solutions and technology are however not limited to security applications and potentially any industry using chemicals of some kind could be addressed by Serstech’s solution. Serstech’s head office is in Sweden and all production is done in Sweden.
Serstech is traded at Nasdaq First North Growth Market and more information about the company can be found at www.serstech.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
MoonLake Immunotherapeutics AG5.11.2025 13:11:23 CET | Press release
MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
ROCKWOOL A/S5.11.2025 13:04:11 CET | Press release
ROCKWOOL A/S – transactions in connection with share buy-back programme
Rockwool A/S5.11.2025 13:04:11 CET | Pressemeddelelse
ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram
Centessa Pharmaceuticals plc5.11.2025 13:00:00 CET | Press release
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program
MoonLake Immunotherapeutics AG5.11.2025 13:00:00 CET | Press release
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom